Our Summary

This research paper is about how to prevent ovarian cancer in patients who have a high genetic risk for it. The most common way to prevent this type of cancer is through a surgery that removes the fallopian tubes and ovaries. However, some patients might want to have children in the future or want to avoid menopause and the health issues that come with it. This paper talks about suitable birth control methods for these patients.

FAQs

  1. What is the primary prevention method for patients with a hereditary risk of ovarian cancer?
  2. What are the alternative options for patients who wish to preserve fertility or delay menopause?
  3. What does the article suggest as appropriate contraception methods for patients with a hereditary risk of ovarian cancer?

Doctor’s Tip

One helpful tip a doctor might tell a patient about bilateral tubal ligation is to discuss the potential risks and benefits of the procedure, including the fact that it is a permanent form of contraception. It is important for the patient to understand that while bilateral tubal ligation is highly effective in preventing pregnancy, it does not protect against sexually transmitted infections. Additionally, the patient should be informed that while the procedure is reversible in some cases, it may not always be successful. It is important for the patient to carefully consider all options and discuss any concerns or questions with their healthcare provider before proceeding with bilateral tubal ligation.

Suitable For

Patients who are recommended bilateral tubal ligation typically include those who have completed their desired family size, those who have a known hereditary risk of ovarian cancer and wish to reduce their risk, and those who wish to avoid the potential side effects of hormonal contraception. Additionally, patients who have medical conditions that contraindicate other forms of contraception may also be recommended for bilateral tubal ligation.

Timeline

Before bilateral tubal ligation:

  1. Patient consults with their healthcare provider to discuss their desire for permanent contraception.
  2. Patient undergoes pre-operative counseling to understand the risks and benefits of the procedure.
  3. Patient schedules the surgery and undergoes pre-operative testing.
  4. Patient undergoes bilateral tubal ligation surgery, which involves blocking or sealing the fallopian tubes to prevent pregnancy.

After bilateral tubal ligation:

  1. Patient may experience some pain and discomfort immediately after the surgery.
  2. Patient is advised to rest and avoid strenuous activities for a few days following the procedure.
  3. Patient may experience some spotting or light bleeding after the surgery.
  4. Patient is instructed to follow up with their healthcare provider for a post-operative check-up.
  5. Patient no longer needs to use other forms of contraception, as bilateral tubal ligation is a permanent method of birth control.
  6. Patient may experience a sense of relief and peace of mind knowing that they are protected from unintended pregnancy.

What to Ask Your Doctor

  1. What are the potential risks and complications associated with bilateral tubal ligation?

  2. How does bilateral tubal ligation affect my fertility and ability to conceive in the future?

  3. Are there any alternative methods of contraception that may be more suitable for me?

  4. What is the success rate of bilateral tubal ligation in preventing pregnancy?

  5. Will I still experience normal menstrual cycles after undergoing this procedure?

  6. How long is the recovery time following bilateral tubal ligation?

  7. Are there any long-term effects or risks associated with bilateral tubal ligation that I should be aware of?

  8. Will I still be at risk for ovarian cancer after undergoing this procedure?

  9. Can I still undergo fertility treatments or procedures in the future if I change my mind about having children?

  10. Are there any factors that may make me a less suitable candidate for bilateral tubal ligation?

Reference

Authors: Joy KM. Journal: JAAPA. 2019 Nov;32(11):37-41. doi: 10.1097/01.JAA.0000586384.47435.31. PMID: 31663894